STEREOTACTIC ABLATIVE RADIOTHERAPY FOR OLIGOMETASTATIC OVARIAN CANCER LYMPH NODE DISEASE: THE MITO-RT3/RAD PHASE II TRIAL: stereotactic radiotherapy for ovarian cancer nodal metastases

• Published in: International journal of radiation oncology, biology, physics
• Main Authors: Macchia, Gabriella, Campitelli, Maura, Pezzulla, Donato, Lucci, Simona, Fodor, Andrei, Russo, Donatella, Balcet, Vittoria, Bonome, Paolo, Durante, Stefano, Draghini, Lorena, Titone, Francesca, D'Agostino, Giuseppe Roberto, Tamburo, Marinella, Ferioli, Martina, Ippolito, Edy, Tortoreto, Francesca, Caravatta, Luciana, De Felice, Francesca, Stefano, Aida Di, Fanelli, Mara, Cilla, Savino, Cosentino, Francesco, Marchetti, Claudia, Salutari, Vanda, Boccia, Serena, Morganti, Alessio Giuseppe, Gambacorta, Maria Antonietta, Fagotti, Anna, Pignata, Sandro, Scambia, Giovanni, Ferrandina, Gabriella, Deodato, Francesco
• Format: Journal Article
• Language: English
• Published: United States 24.09.2024
• Subjects: Oligorecurrences; Stereotactic body radiotherapy; Metastases directed therapy; Oligometastasis; Personalized medicine; Lymph nodes; Ovarian cancer

MITO-RT3/RAD (NCT04593381) is a prospective multicenter Phase II trial designed to assess the effectiveness and safety of stereotactic body radiotherapy (SBRT) in patients diagnosed with oligometastatic ovarian cancer (oligo-MPR-OC). In this report, we provide the results of the trial in the setting...